Regulation Tracker
Category 1 peptides: the framework that decides your access
The FDA's category framework determines what your compounding pharmacy will actually fill. It's how a peptide leaves the prescribed market without any ban ever being announced.
The FDA sorts nominated bulk drug substances into categories that determine whether a compounding
pharmacy can use them while the agency completes its evaluation. In practice, this is the framework that
decides what your provider can actually get filled.
| Category | What it means in practice |
|---|
| Category 1 | Nominated substances the FDA is evaluating that may be used in compounding under enforcement discretion while review is pending. This is the working category most peptides want to be in. |
| Category 2 | Substances the FDA has identified as raising significant safety risks. Compounding with these is not covered by enforcement discretion. |
| Category 3 | Nominated but with insufficient supporting information to evaluate. |
Category status is not permanent
Compounds move between categories as the FDA completes evaluation. A Category 2 designation, or removal
from Category 1, is the mechanism by which a peptide effectively leaves the prescribed market —
without any "ban" ever being announced. That's why this framework matters more than headlines suggest.
Why this decides your access
Your telehealth provider doesn't make the peptide — a 503A compounding pharmacy does. That
pharmacy will not risk its license compounding a substance that lacks a defensible regulatory footing. So
when a compound's category status weakens, the practical effect isn't a dramatic ban announcement: it's
that pharmacies quietly stop filling it, and your provider quietly removes it from the menu.
The July 2026 PCAC meeting is a category decision
The seven peptides under review (BPC-157, KPV, TB-500, MOTS-C, DSIP, Semax, Epitalon) are being evaluated
for the 503A approved bulks list — the formal end-state of this process.
See what's under review →What to ask your provider
"What is the current regulatory status of the specific compound you're prescribing me, and what happens
to my protocol if it changes?" A provider that can answer that clearly is one that's paying attention. A
provider that deflects is one that will remove the compound from your menu without warning.
FAQ
What are Category 1 peptides?
Category 1 refers to nominated bulk drug substances that the FDA is evaluating and that may be used in compounding under enforcement discretion while that review is pending. It's the working category that keeps a peptide available through compounding pharmacies.
What does Category 2 mean?
Category 2 substances have been identified by the FDA as raising significant safety risks. Compounding with them is not covered by enforcement discretion, which effectively removes them from the prescribed market.
How do I know what category my peptide is in?
Ask your provider directly, and check our
status tracker, which we re-verify monthly. Category status changes without public fanfare, so the first sign is often that your pharmacy simply stops filling it.
Medical disclaimer: Veritide is an independent consumer-research publication, not a healthcare provider or pharmacy. This page is informational and is not medical advice. Compounded medications are not FDA-approved as finished products. Always consult a licensed clinician before starting any peptide or GLP-1 therapy.